A cross-sectional study: The correlation of pro-angiogenic factors expression level and epithelial ovarian cancer staging

Teguh Prakosa; Ambar Mudigdo; Bambang Purwanto; Brian Wasita; Risya Cilmiaty; Vitri Widianingsih

doi:10.15562/bmj.v9i1.1605

A cross-sectional study: The correlation of pro-angiogenic factors expression level and epithelial ovarian cancer staging

Teguh Prakosa ,

Ambar Mudigdo ,

Bambang Purwanto ,

Brian Wasita ,

Risya Cilmiaty ,

Vitri Widianingsih ,

PDF |
DOI: https://doi.org/10.15562/bmj.v9i1.1605 |
Published: 2020-04-01

Abstract

Background: Cancer is caused by uncontrolled cell growth and angiogenesis as a vital component in tumor growth and metastasis. Angiogenesis provides nutrients needed by cancer cells in order to grow. Angiogenesis is triggered by pro-angiogenic mediators and overexpression of these mediators have been associated with malignant phenotype of ovarian cancer. It is thought that the more advanced tumors have higher tumor cell survival, proliferation, invasion, and angiogenesis, so that it will show higher expression of pro-angiogenesis mediators.

Objective: To examine the differences in nerve growth factor (NGF), tyrosin kinase receptor A (TrkA), and vascular endothelial growth factor (VEGF) expression level in different stages of epithelial ovarian cancer.

Patients and methods: This is a retrospective cross-sectional study conducted from June to August 2019 in the Department of Obstetrics and Gynecology in association with the Department of Anatomic Pathology of Dr. Moewardi General Hospital, Surakarta, Indonesia. The staging of the epithelial ovarian cancer was determined using the FIGO 2014 staging system. NGF, TrkA, and VEGF expression level were determined using immunohistochemical examination.

Results:The samples were 53 formalin-fixed, paraffin-embedded ovary, its adnexa, uterus, and lymph nodes tissue blocks of epithelial ovarian cancer patients. There are statistically significant differences in the proportion of NGF, TrkA, and VEGF level of expression in different stages of epithelial ovarian cancer (p<0.05).

Conclusion: There are statistically significant differences in NGF, TrkA, and VEGF level of expression in different stages of epithelial ovarian cancer.

References

Kim A, Ueda Y, Naka T, et al. Therapeutics strategies in epithelial ovarian cancer. Journal of Experimental & Clinical Cancer Research 2012;31:14.
Ranjbar R, Nejarollahi F, Ahmadi ASN, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in patients with serous ovarian carcinoma and their clinical significance. Iran J Cancer Preven 2015;8(4):e3428.
Retamales-Ortega R, Orostica L, Vera C, et al. Role of nerve growth factor (NGF) and miRNAs in epithelial ovarian cancer. Int J Mol Sci 2017;18:507-524.
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017;14:9-32
Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician 2016;93(11):937-944.
Odegaard E, Staff AC, Abeler VM, et al. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma. Human Pathology 2007;38:140-146.
Li B, Cai S, Zhao Y, et al. Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/Î²-catenin pathway. Oncotarget 2016;7(49):81026-81048.
Tapia V, Gabler F, Munoz M, et al. Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer. Tapia V, Gabler F, Munoz M, et al. Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer. Gynecologic Oncology 2011;121:13-23.
Duncan TJ, Al-Attar A, Rolland P, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 2008;14(10):3030-3035.
Egiz M, Masoud A, Ellakwa H, et al. Vascular endothelial growth for correlation with clinicopathological parameters in ovarian cancer. Int J Reprod Contracept Obstet Gynecol 2019;8(4):1700-1705.
Vera C, Tapia V, Vega M, et al. Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis. Journal of Ovarian Research 2014;7:82-90.
Wang W, Leng T, Zhang L, et al. Correlation of VEGF expression with transvaginal color Doppler ultrasound blood flow parameters, angiogenesis, and cancer cell proliferation activity in patients with ovarian cancer. Int J Clin Exp Med 2018;11(12):!3763-13768.
Ravikumar G, Crasta JA. Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation. South Asian J Cancer 2013;2(2):87-90.
Javadi S, Ganeshan DM, Qayyum A, et al. Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR 2016;206:1351-1360.
Mukherjee S, Pal M, Mukhopadhyay S, et al. VEGF expression to support targeted therapy in ovarian surface epithelial neoplasms. Journal of Clinical and Diagnostic Research 2017;11(4):EC43-EC46.
Guo BQ, Lu WQ. The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer. Oncotarget 2018;9(55):30552-30560.
Yu X, Liu Z, Hou R, et al. Nerve growth factor and its receptors on onset and diagnosis of ovarian cancer. Oncology Letters 2017;14:2864-2868.
Molloy NH, Read DE, Gorman AM. Nerve growth factor in cancer cell death and survival. Cancers 3:510-530.

[1] Kim A, Ueda Y, Naka T, et al. Therapeutics strategies in epithelial ovarian cancer. Journal of Experimental & Clinical Cancer Research 2012;31:14.

[2] Ranjbar R, Nejarollahi F, Ahmadi ASN, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in patients with serous ovarian carcinoma and their clinical significance. Iran J Cancer Preven 2015;8(4):e3428.

[3] Retamales-Ortega R, Orostica L, Vera C, et al. Role of nerve growth factor (NGF) and miRNAs in epithelial ovarian cancer. Int J Mol Sci 2017;18:507-524.

[4] Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017;14:9-32

[5] Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician 2016;93(11):937-944.

[6] Odegaard E, Staff AC, Abeler VM, et al. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma. Human Pathology 2007;38:140-146.

[7] Li B, Cai S, Zhao Y, et al. Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/Î²-catenin pathway. Oncotarget 2016;7(49):81026-81048.

[8] Tapia V, Gabler F, Munoz M, et al. Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer. Tapia V, Gabler F, Munoz M, et al. Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer. Gynecologic Oncology 2011;121:13-23.

[9] Duncan TJ, Al-Attar A, Rolland P, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 2008;14(10):3030-3035.

[10] Egiz M, Masoud A, Ellakwa H, et al. Vascular endothelial growth for correlation with clinicopathological parameters in ovarian cancer. Int J Reprod Contracept Obstet Gynecol 2019;8(4):1700-1705.

[11] Vera C, Tapia V, Vega M, et al. Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis. Journal of Ovarian Research 2014;7:82-90.

[12] Wang W, Leng T, Zhang L, et al. Correlation of VEGF expression with transvaginal color Doppler ultrasound blood flow parameters, angiogenesis, and cancer cell proliferation activity in patients with ovarian cancer. Int J Clin Exp Med 2018;11(12):!3763-13768.

[13] Ravikumar G, Crasta JA. Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation. South Asian J Cancer 2013;2(2):87-90.

[14] Javadi S, Ganeshan DM, Qayyum A, et al. Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR 2016;206:1351-1360.

[15] Mukherjee S, Pal M, Mukhopadhyay S, et al. VEGF expression to support targeted therapy in ovarian surface epithelial neoplasms. Journal of Clinical and Diagnostic Research 2017;11(4):EC43-EC46.

[16] Guo BQ, Lu WQ. The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer. Oncotarget 2018;9(55):30552-30560.

[17] Yu X, Liu Z, Hou R, et al. Nerve growth factor and its receptors on onset and diagnosis of ovarian cancer. Oncology Letters 2017;14:2864-2868.

[18] Molloy NH, Read DE, Gorman AM. Nerve growth factor in cancer cell death and survival. Cancers 3:510-530.

A cross-sectional study: The correlation of pro-angiogenic factors expression level and epithelial ovarian cancer staging

Abstract

References

How to Cite

Search Panel